Treatment with a platinum-based doublet incorporating a newer, third-generation cytotoxic agent is the recommended therapy for good-performance-status patients with advanced NSCLC, yielding an approximate response rate of 30%, median survival of 8-12 months, 1-year survival of 30%, and 2-year ...
Unfortunately, NSCLC is more resistant to chemotherapy and radiotherapy than SCLC.10 The survival rate for the next 5 years is significantly higher - 30%.10 The likelihood of effective treatment increases with the early detection of cancer.11,15,16 The treatment method depends on the type o...
Socinski and Thomas E. Stinchcombe of the University of North Carolina in Chapel Hill claimed that prolonging the duration of first-line chemotherapy without a clear signal of survival benefit during subsequent therapies is not justified.EBSCO_AspInpharma Weekly...
In this study, we investigated the association of the positively selected SNPs of eIF3a with the response to and toxicity of platinum-based chemotherapy in Chinese patients with non-small cell lung cancer (NSCLC). SNP data for eIF3a locus were downloaded from HapMap database. For each SNP, ...
MiRNA-21: a biomarker predictive for platinum-based adjuvant chemotherapy response in patients with non-small cell lung cancer. PURPOSE: To investigate the possible role of microRNAs in the resistance to platinum based chemotherapy in non-small cell lung cancer (NSCLC), explore thei... G Wen,L...
9092 Background: Platinum-based chemo is a standard first-line (1L) therapy for NSCLC lacking actionable gene alterations. Preclinical evidence suggests that chemo can play an immunomodulatory role and induce tumor antigen release, supporting combining chemo with immunotherapy. Atezo is a humanized and...
(1.2) • as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC. (1.2) Malignant Pleural Mesothelioma (MPM) • in combination with pemetrexed and platinum chemotherapy, as first-line ...
While platinum-based chemotherapy remains an important therapy for treatment of NSCLC, nonplatinum combinations may be a reasonable alternative for patients. These docetaxel/nonplatinum combinations warrant further evaluation in randomized trials to define their optimal role as standard therapy for NSCLC....
Chemotherapy based on platinum compounds is the standard treatment for NSCLC patients with EGFR wild type, and is also used as second line in mutated EGFR patients. Nevertheless, this therapy presents poor clinical outcomes. ERCC1, ERCC2, XRCC1, MDM2, MTHFR, MTR, and SLC19A1 gene polymorphisms...
The purpose of this study was to investigate the relationship between the level of expression of ATP-binding cassette (ABC) transporter proteins, and response to chemotherapy and prognosis in advanced non-small cell lung cancer (NSCLC). Expression of ABC transporter proteins, including P-glycoprotein...